We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV - Free Report) ended the recent trading session at $227.73, demonstrating a +1.32% change from the preceding day's closing price. This change outpaced the S&P 500's 0.5% gain on the day. At the same time, the Dow added 0.7%, and the tech-heavy Nasdaq gained 0.31%.
The stock of drugmaker has risen by 6.64% in the past month, leading the Medical sector's gain of 5.49% and the S&P 500's loss of 0.23%.
Market participants will be closely following the financial results of AbbVie in its upcoming release. The company's upcoming EPS is projected at $3.79, signifying a 27.61% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.8 billion, up 8.93% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.3 per share and revenue of $67.32 billion. These results would represent year-over-year changes of +43% and +10.07%, respectively.
Investors might also notice recent changes to analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.12% downward. AbbVie presently features a Zacks Rank of #3 (Hold).
From a valuation perspective, AbbVie is currently exchanging hands at a Forward P/E ratio of 15.72. This denotes a premium relative to the industry average Forward P/E of 15.58.
It is also worth noting that ABBV currently has a PEG ratio of 0.69. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.71.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 113, finds itself in the top 47% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
AbbVie (ABBV) Rises Higher Than Market: Key Facts
AbbVie (ABBV - Free Report) ended the recent trading session at $227.73, demonstrating a +1.32% change from the preceding day's closing price. This change outpaced the S&P 500's 0.5% gain on the day. At the same time, the Dow added 0.7%, and the tech-heavy Nasdaq gained 0.31%.
The stock of drugmaker has risen by 6.64% in the past month, leading the Medical sector's gain of 5.49% and the S&P 500's loss of 0.23%.
Market participants will be closely following the financial results of AbbVie in its upcoming release. The company's upcoming EPS is projected at $3.79, signifying a 27.61% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.8 billion, up 8.93% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.3 per share and revenue of $67.32 billion. These results would represent year-over-year changes of +43% and +10.07%, respectively.
Investors might also notice recent changes to analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.12% downward. AbbVie presently features a Zacks Rank of #3 (Hold).
From a valuation perspective, AbbVie is currently exchanging hands at a Forward P/E ratio of 15.72. This denotes a premium relative to the industry average Forward P/E of 15.58.
It is also worth noting that ABBV currently has a PEG ratio of 0.69. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.71.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 113, finds itself in the top 47% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.